ACHL - Achilles-led group gets Euro4M funding for personalized cell therapy manufacturing
- Achilles Therapeutics ( NASDAQ: ACHL ) said it is leading a consortium which has been awarded a €4M grant under an EU program to develop a smart bioprocessing manufacturing platform for personalized cell therapies.
- The company said Horizon Europe — an EU funding program for research and innovation — granted the funding to the consortium, which also includes Leibniz University Hannover (the project coordinator), the Cell and Gene Therapy Catapult, and the Fundacion para la Investigacion del Hospital Universitario la Fe de la Comunidad Valenciana.
- Achilles said the project, named SMARTER, will develop a smart bioprocessing manufacturing platform for personalized cell therapies which aim to incorporate advanced inline spectroscopic sensors and smart machine-learning process control systems.
- Of the €4M allocated to the project, ~€1.4M will be provided to Achilles via the Horizon Europe Guarantee from UK Research and Innovation, the company said in a July 21 press release.
For further details see:
Achilles-led group gets €4M funding for personalized cell therapy manufacturing